{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:51:38Z","timestamp":1762005098457,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002484","name":"Micron Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jgar.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T11:45:17Z","timestamp":1562586317000},"page":"106-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Longitudinal analysis of the in vitro activity of ceftazidime\/avibactam versus Enterobacteriaceae, 2012\u20132016"],"prefix":"10.1016","volume":"19","author":[{"given":"Elmano","family":"Ramalheira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.07.003_bib0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with Gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2019.07.003_bib0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1469-0691.2007.01850.x","article-title":"Prevalence and spread of extended-spectrum \u03b2-lactamases-producing Enterobacteriaceae in Europe","volume":"14","author":"Cant\u00f3n","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2019.07.003_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenemase-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.003_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary infection, pneumonia and sepsis","volume":"17","author":"Zilderberg","year":"2017","journal-title":"BMC Infect Dis"},{"year":"2017","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"World Health Organization (WHO)","key":"10.1016\/j.jgar.2019.07.003_bib0025"},{"key":"10.1016\/j.jgar.2019.07.003_bib0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","article-title":"Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \u2018precision medicine\u2019 to antimicrobial chemotherapy?","volume":"17","author":"Perez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2016.09.002","article-title":"The rapid spread of carbapenem-resistant Enterobacteriaceae","volume":"29","author":"Potter","year":"2016","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jgar.2019.07.003_bib0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jgar.2013.01.005","article-title":"Carbapenemases: partners in crime","volume":"1","author":"Bush","year":"2013","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2019.07.003_bib0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3389\/fmicb.2016.00895","article-title":"Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods","volume":"7","author":"Lee","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2019.07.003_bib0050","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.jgar.2019.07.003_bib0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","article-title":"Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases","volume":"82","author":"Papp-Wallace","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1128\/AAC.04218-14","article-title":"In vitro antibacterial activity of the ceftazidime\/avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases","volume":"59","author":"Levasseur","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0065","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime\/avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime\/avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"year":"2018","series-title":"AVYCAZ\u00ae package insert","author":"Allergan Inc","key":"10.1016\/j.jgar.2019.07.003_bib0075"},{"key":"10.1016\/j.jgar.2019.07.003_bib0080","unstructured":"Pfizer Pharmaceuticals. Zavicefta summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf [Accessed 14 June 2018]."},{"key":"10.1016\/j.jgar.2019.07.003_bib0085","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/AAC.02286-15","article-title":"Activity of ceftazidime\u2013avibactam against extended-spectrum- and AmpC \u03b2-lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014","volume":"60","author":"Karlowsky","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime\u2013avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012\u20132015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0100","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dky266","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012\u20132015","volume":"73","author":"Kazmierczak","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0105","article-title":"Longitudinal analysis of the in vitro activity of ceftazidime\u2013avibactam versus Enterobacteriaceae collected for the INFORM global surveillance study from 2012 to 2016","author":"Estabrook","year":"2018","journal-title":"28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 21\u201324 April 2018"},{"key":"10.1016\/j.jgar.2019.07.003_bib0110","series-title":"CLSI document M07-A10","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards\u2014tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"year":"2018","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","key":"10.1016\/j.jgar.2019.07.003_bib0115"},{"key":"10.1016\/j.jgar.2019.07.003_bib0120","series-title":"CLSI supplement M100S","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.jgar.2019.07.003_bib0125","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01820-16","article-title":"In vitro activity of ceftazidime\u2013avibactam against isolates in a Phase 3 open-label clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible Gram-negative pathogens","volume":"61","author":"Stone","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0135","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract isolates","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime\/avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.003_bib0145","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/IDR.S175679","article-title":"In vitro activity of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)","volume":"11","author":"Jean","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2019.07.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02431-18","article-title":"Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa","volume":"63","author":"Yin","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0155","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistant patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0160","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/AAC.01870-15","article-title":"Correlation of \u03b2-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program","volume":"60","author":"Bradford","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0165","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.003_bib0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2019.07.003_bib0175","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00567-17","article-title":"Meropenem\u2013vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.07.003_bib0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01904-17","article-title":"In vitro activity of meropenem\/vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"year":"2017","series-title":"EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Version 2.0","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","key":"10.1016\/j.jgar.2019.07.003_bib0185"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519301699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:37Z","timestamp":1761990817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519301699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"alternative-id":["S2213716519301699"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.003","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal analysis of the in vitro activity of ceftazidime\/avibactam versus Enterobacteriaceae, 2012\u20132016","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}